retatrutide fda approval status november 2025 This weight-loss drug hasn't been approved by the FDA. Doctors are prescribing it anyway Retatrutide Promises Big Weight Loss,

That same year, Zafgen demonstrated beloranibs efficacy, a MetAP2 inhibitor, in a Phase III trial, but safety concerns ultimately led to its discontinuation

[DOI] [PMC free article] [PubMed] [Google Scholar] 356.Zhang, Y

Tirzepatide also reduced left ventricular mass and pericardial adipose tissue 41

Of self-insured employers, who generally have significant latitude in what they reimburse, only about 20% cover these drugs for weight loss

myopathy risk with certain drug combinations) Bottom line To minimize transplant vasculopathy, prevention must directly counter the three immunosuppression-linked cardiometabolic mechanisms listed: CNI hypertension and metabolic effects, steroid-induced hypercholesterolemia, and mTOR inhibitorassociated dyslipidemia

PMID 36723855